Vimian Group ABVIMGF 69 EBIT per Share is $0.16 as of Mar. 2026. GuruFocus rates VIMGF with a GF Score™ of 69/100 and a GF Value™ of $3.29. The stock has 2 warning signs investors should review. Among 168 Medical Diagnostics & Research companies, Vimian Group AB ranks worse than 59.52% on this metric.
Vimian Group AB's EBIT per Share for the
three
months ended in Mar. 2026 was $0.05.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.16.
During the past 12 months, the average EBIT per Share Growth Rate of Vimian Group AB was 34.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 5.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -11.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Vimian Group AB's EBIT per Share or its related term are showing as below:
VIMGF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -36.9 Med: 10.5 Max: 241.5
Current: 5.4
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Vimian Group AB was 241.50% per year. The lowest was -36.90% per year. And the median was 10.50% per year.
VIMGF's 3-Year EBIT Growth Rate is ranked worse than 59.52% of 168
companies
in the Medical Diagnostics & Research industry
Industry Median: 12.75
vs VIMGF: 5.40
Vimian Group AB's EBIT for the
three
months ended in Mar. 2026 was $24.4 Mil.
Vimian Group AB (OTCPK:VIMGF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Vimian Group AB EBIT per Share Related Terms
Vimian Group AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Vimian Group AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimian Group AB (VIMGF) has a EBIT per Share of $0.16 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Vimian Group AB and its competitors. According to the industry distribution chart, Vimian Group AB ranks #100 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 59.5%.
Is Vimian Group AB's EBIT per Share too high?
Vimian Group AB's current EBIT per Share is $0.16. The Medical Diagnostics & Research industry median EBIT per Share is 12.75. Vimian Group AB's value of $0.16 is 98.7% below this industry median. Based on the distribution chart, Vimian Group AB ranks #100 out of 168 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Vimian Group AB has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #100 out of 168 companies for EBIT per Share. This places Vimian Group AB in the lower half of its industry. The industry median EBIT per Share is 12.75. Vimian Group AB's value of $0.16 is 98.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.75, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimian Group AB's current EBIT per Share of $0.16 is 98.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Vimian Group AB and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimian Group AB's current EBIT per Share is $0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current EBIT per Share of $0.16. The stock's GF Value™ is $3.29, compared to a current price of $2.77 — trading 15.8% below its estimated fair value. The current EBIT per Share is $0.16 and 98.7% below the Medical Diagnostics & Research industry median of 12.75. Vimian Group AB's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current EBIT per Share is $0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (VIMGF) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of $2.77 is trading 15.8% below its estimated GF Value™ of $3.29.
Key valuation signals for VIMGF:
EBIT per Share: $0.16
GF Value™: $3.29 vs. price of $2.77 (15.8% below fair value)
Industry Position: 98.7% below the Medical Diagnostics & Research median (#100 of 168)
No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
69GF Score
Get the complete analysis for VIMGF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIMGF has been successfully added to your 
